Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 6/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.48 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794565 | 1.00 | KCNQ2 (0.48) | KCNQ2KCNQ3KCNQ4KCNQ5ALOX5 | |
| SCHEMBL3104063 | 0.90 | ALOX5 (0.55) | KCNQ2ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL30795194 | 0.90 | ALOX5 (0.55) | KCNQ2ALOX5EPHX2KCNT1HDAC6 | |
| SCHEMBL30794362 | 0.89 | KCNQ2 (0.46) | KCNQ2KCNQ3KCNQ4KCNQ5ALOX5 | |
| SCHEMBL3099402 | 0.89 | KCNQ2 (0.46) | KCNQ2KCNQ3KCNQ4KCNQ5ALOX5 | |
| SCHEMBL30795774 | 0.88 | ALOX5 (0.43) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL3106729 | 0.88 | ALOX5 (0.43) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL27749690 | 0.88 | GAA (0.48) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL30796014 | 0.87 | ALOX5 (0.42) | KCNQ2KCNQ3ALOX5EPHX2KCNT1 | |
| SCHEMBL3102368 | 0.87 | ALOX5 (0.42) | KCNQ2KCNQ3ALOX5EPHX2KCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| US-20060264496-A1 | Substituted indoline and indole derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | claimed |
| JP-2006524641-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1631546-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-03-08 | — | — | EP | claimed |
| WO-2004096767-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
| US-20060264496-A1 | Substituted indoline and indole derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | disclosed |
| EP-1631546-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004096767-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | KCNQ2 5/4885KCNQ3 4/4885KCNQ4 1/4885 |
| US-20060264496-A1 | Substituted indoline and indole derivatives | IDO1, IDO2, INMT | KCNQ2 1405/4885KCNQ3 1605/4885KCNQ4 2233/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | KCNQ2 1/4885KCNQ3 4/4885KCNQ4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.